BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31031216)

  • 1. Role of P53, E-cadherin and BRAF as predictors of regional nodal recurrence for papillary thyroid cancer.
    Ali KM; Awny S; Ibrahim DA; Metwally IH; Hamdy O; Refky B; Abdallah A; Abdelwahab K
    Ann Diagn Pathol; 2019 Jun; 40():59-65. PubMed ID: 31031216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF
    Kim JK; Seong CY; Bae IE; Yi JW; Yu HW; Kim SJ; Won JK; Chai YJ; Choi JY; Lee KE
    Ann Surg Oncol; 2018 Jun; 25(6):1775-1781. PubMed ID: 29611028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of cell-adhesion molecules in histological variants of papillary thyroid carcinoma.
    Andriescu EC; Căruntu ID; Giuşcă SE; Lozneanu L; Ciobanu Apostol DG
    Rom J Morphol Embryol; 2018; 59(3):721-727. PubMed ID: 30534810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.
    Chen D; Qi W; Zhang P; Zhang Y; Liu Y; Guan H; Wang L
    Pathol Res Pract; 2018 Feb; 214(2):303-307. PubMed ID: 29254799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of Dickkopf-1 in wild-type BRAF papillary thyroid cancer via regulation of β-catenin/E-cadherin signaling.
    Cho SW; Kim YA; Sun HJ; Ahn HY; Lee EK; Yi KH; Oh BC; Park DJ; Cho BY; Park YJ
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1641-9. PubMed ID: 24848709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.
    O'Neill CJ; Bullock M; Chou A; Sidhu SB; Delbridge LW; Robinson BG; Gill AJ; Learoyd DL; Clifton-Bligh R; Sywak MS
    Surgery; 2010 Dec; 148(6):1139-45; discussion 1145-6. PubMed ID: 21134544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
    Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
    Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
    Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
    JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity.
    Zoghlami A; Roussel F; Sabourin JC; Kuhn JM; Marie JP; Dehesdin D; Choussy O
    Eur Ann Otorhinolaryngol Head Neck Dis; 2014 Feb; 131(1):7-13. PubMed ID: 23845288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry.
    McKelvie PA; Chan F; Yu Y; Waring P; Gresshoff I; Farrell S; Williams RA
    Pathology; 2013 Dec; 45(7):637-44. PubMed ID: 24247620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
    Gao WL; Wie LL; Chao YG; Wie L; Song TL
    Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
    Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
    Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathologic and molecular features of cribriform morular variant of papillary thyroid carcinoma].
    Cui XJ; Zhao HO; Su P; Chen J; Zhang RY; Pan Y; Ouyang XM; Liu J; Zhang JQ; Yang Y; Yang R; Ding L; Liu ZY
    Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):354-359. PubMed ID: 29783802
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.